Advertisement

Molecular Medicine

, Volume 23, Issue 1, pp 83–91 | Cite as

IL-37 Suppresses MyD88-mediated Inflammatory Responses in Human Aortic Valve Interstitial Cells

  • Qiong Zhan
  • Qingchun Zeng
  • Rui Song
  • Yufeng Zhai
  • Dingli Xu
  • David A. Fullerton
  • Charles A. Dinarello
  • Xianzhong Meng
Research Article

Abstract

Calcific aortic valve disease (CAVD) is common among the elderly, and aortic valve interstitial cells (AVICs) exhibit unique inflammatory and osteogenic responses to proinflammatory stimulation, which plays an important role in valvular fibrosis and calcification. Thus, suppression of AVIC proinflammatory response may have therapeutic utility for the prevention of CAVD progression. Interleukin (IL)-37, an antiinflammatory cytokine, reduces tissue inflammation. This study aimed to test the hypothesis that IL-37 suppresses human AVIC inflammatory responses to Toll-like receptor (TLR) agonists. Human AVICs were exposed to Pam3CSK4, poly(I:C) and lipopolysaccharide in the presence and absence of recombinant human IL-37. Stimulation of TLR4 increased the production of intercellular adhesion molecule-1, IL-6, IL-8 and monocyte chemoattractant protein-1. Knockdown of myeloid differentiation factor 88 (MyD88) or TIR-domain-containing adaptor-inducing interferon-β differentially affected inflammatory mediator production following TLR4 stimulation. IL-37 reduced production of these inflammatory mediators induced by TLR4. Moreover, knockdown of IL-37 enhanced induction of these mediators by TLR4. IL-37 also suppressed inflammatory mediator production induced by the MyD88-dependent TLR2, but had no effect on the inflammatory responses to the TRIF-dependent TLR3. Furthermore, IL-37 inhibited NF-κB activation induced by TLR2 or TLR4 through a mechanism dependent of IL-18 receptor α-chain. Activation of TLR2, TLR3 or TLR4 upregulates the production of inflammatory mediators in human AVICs. IL-37 suppresses MyD88-mediated responses to reduce inflammatory mediator production following stimulation of TLR2 and TLR4. This antiinflammatory cytokine may be useful for suppression of aortic valve inflammation elicited by MyD88-dependent TLR signaling.

Notes

Acknowledgments

The authors thank Benjamin Posorske and Lihua Ao for their technical support.

This study was supported in part by National Institutes of Heart, Lung and Blood grants HL121776 and HL106582 (to XM), National Institute of Allergy and Infectious Disease Grant AI15414 (to CAD) and National Natural Sciences Foundation of China grant 81570352 (to QZ). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

References

  1. 1.
    Go AS, et al. (2013) Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation. 127: e6–e245.Google Scholar
  2. 2.
    Hutcheson JD, Aikawa E, Merryman WD. (2014) Potential drug targets for calcific aortic valve disease. Nat. Rev. Cardiol. 11:218–31.CrossRefGoogle Scholar
  3. 3.
    Rajamannan NM, et al. (2011) Calcific Aortic Valve Disease: Not Simply a Degenerative Process. A Review and Agenda for Research From the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive Summary: Calcific Aortic Valve Disease-2011 Update. Circulation. 124:1783–91.CrossRefGoogle Scholar
  4. 4.
    Miller JD, Weiss RM, Heistad DD. (2011) Calcific aortic valve stenosis: methods, models, and mechanisms. Circ. Res. 108:1392–1412.CrossRefGoogle Scholar
  5. 5.
    Boström KI, Rajamannan NM, Towler DA. (2011) The regulation of valvular and vascular sclerosis by osteogenic morphogens. Circ. Res. 109:564–77.CrossRefGoogle Scholar
  6. 6.
    Dweck MR, et al. (2012) Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis. Circulation. 125:76–86.CrossRefGoogle Scholar
  7. 7.
    Hjortnaes J, et al. (2010) Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation. Eur. Heart J. 31:1975–84.CrossRefGoogle Scholar
  8. 8.
    Aikawa E, et al. (2007) Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation. 115:377–86.CrossRefGoogle Scholar
  9. 9.
    Weiss RM, Miller JD, Heistad DD. (2013) Fibrocalcific Aortic Valve Disease: Opportunity to Understand Disease Mechanisms Using Mouse Models. Circ. Res. 113:209–22.CrossRefGoogle Scholar
  10. 10.
    Alexopoulos A, et al. (2010) Bone regulatory factors NFATc1 and Osterix in human calcific aortic valves. Int. J. Cardiol. 139:142–9.CrossRefGoogle Scholar
  11. 11.
    Rabkin-Aikawa E, Farber M, Aikawa M, Schoen FJ. (2004) Dynamic and reversible changes of interstitial cell phenotype during remodeling of cardiac valves. J. Heart Valve Dis. 13:841–7.PubMedGoogle Scholar
  12. 12.
    Meng X, et al. (2008) Expression of functional Toll-like receptors 2 and 4 in human aortic valve interstitial cells: potential roles in aortic valve inflammation and stenosis. Am. J. Physiol. Cell Physiol. 294: C29–C35.CrossRefGoogle Scholar
  13. 13.
    Song R, et al. (2012) Biglycan induces the expression of osteogenic factors in human aortic valve interstitial cells via Toll-like receptor-2. Arterioscler. Thromb. Vasc. Biol. 32:2711–20.CrossRefGoogle Scholar
  14. 14.
    Akira S, Takeda K. (2004) Toll-like receptor signalling. Nat. Rev. Immunol. 4:499–511.CrossRefGoogle Scholar
  15. 15.
    Piccinini A, Midwood K. (2010) DAMPening inflammation by modulating TLR signalling. Mediators Inflamm. 2010:672395.CrossRefGoogle Scholar
  16. 16.
    Akira S, Uematsu S, Takeuchi O. (2006) Pathogen recognition and innate immunity. Cell. 124:783–801.CrossRefGoogle Scholar
  17. 17.
    Kaisho T, Akira S. (2006) Toll-like receptor function and signaling. J. Allergy Clin. Immunol. 117:979–87.CrossRefGoogle Scholar
  18. 18.
    Fang Y, Hu J. (2011) Toll-like receptor and its roles in myocardial ischemic/reperfusion injury. Med. Sci. Monit. 17: RA100–09.CrossRefGoogle Scholar
  19. 19.
    Björkbacka H. (2006) Multiple roles of Toll-like receptor signaling in atherosclerosis. Curr. Opin. Lipidol. 17:527–33.CrossRefGoogle Scholar
  20. 20.
    Zeng Q, et al. (2013) Notch1 promotes the pro-osteogenic response of human aortic valve interstitial cells via modulation of ERK1/2 and nuclear factor-κB activation. Arterioscler. Thromb. Vasc. Biol. 33:1580–90.CrossRefGoogle Scholar
  21. 21.
    Dinarello CA, et al. (2016) Suppression of innate inflammation and immunity by interleukin-37. Eur. J. Immunol. 46:1067–81.CrossRefGoogle Scholar
  22. 22.
    Boraschi D, et al. (2011) IL-37: a new anti-inflammatory cytokine of the IL-1 family. Eur. Cytokine Netw. 22:127–47.PubMedGoogle Scholar
  23. 23.
    Zeng Q, et al. (2017) Interleukin-37 suppresses the osteogenic responses of human aortic valve interstitial cells in vitro and alleviates valve lesions in mice. Proc. Natl. Acad. Sci. USA. 114:1631–6.CrossRefGoogle Scholar
  24. 24.
    Messier RH, et al. (1994) Dual structural and functional phenotypes of the porcine aortic valve interstitial population: characteristics of the leaflet myofibroblast. J. Surg. Res. 57:1–21.CrossRefGoogle Scholar
  25. 25.
    Pimentel MM, Fuck RA. (1992) Neoproterozoic crustal accretion in central Brazil. Geology. 20:375–9.CrossRefGoogle Scholar
  26. 26.
    Nold-Petry CA, et al. (2015) IL-37 requires the receptors IL-18R [alpha] and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction. Nat. Immunol. 16:354–65.CrossRefGoogle Scholar
  27. 27.
    Mohler ER, et al. (2001) Bone formation and inflammation in cardiac valves. Circulation. 103:1522–28.CrossRefGoogle Scholar
  28. 28.
    New SE, Aikawa E. (2011) Cardiovascular calcification: an inflammatory disease. Circ. J. 75:1305–13.CrossRefGoogle Scholar
  29. 29.
    Yang X, Fullerton DA, Su X, Ao L, Meng X. (2009) Pro-osteogenic phenotype of human aortic valve interstitial cells is associated with higher levels of Toll-like receptors 2 and 4 and enhanced expression of bone morphogenetic protein 2. J. Am. Coll. Cardiol. 53:491–500.CrossRefGoogle Scholar
  30. 30.
    Zeng Q, et al. (2014) Augmented osteogenic responses in human aortic valve cells exposed to oxLDL and TLR4 agonist: a mechanistic role of Notch1 and NF-κB interaction. PLoS One. 9: e95400.CrossRefGoogle Scholar
  31. 31.
    Zeng Q, et al. (2012) Cross-talk between the tolllike receptor 4 and notch1 pathways augments the inflammatory response in the interstitial cells of stenotic human aortic valves. Circulation. 126: S222–30.CrossRefGoogle Scholar
  32. 32.
    Yamamoto M, et al. (2003) Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science. 301:640–3.CrossRefGoogle Scholar
  33. 33.
    Takeda K, Akira S. (2004) TLR signaling pathways. Semin. Immunol. 16:3–9.CrossRefGoogle Scholar
  34. 34.
    Schober A. (2008) Chemokines in vascular dysfunction and remodeling. Arterioscler. Thromb. Vasc. Biol. 28:1950–9.CrossRefGoogle Scholar
  35. 35.
    Galkina E, Ley K. (2007) Vascular adhesion molecules in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27:2292–2301.CrossRefGoogle Scholar
  36. 36.
    El Husseini D, et al. (2014) P2Y2 receptor represses IL-6 expression by valve interstitial cells through Akt: implication for calcific aortic valve disease. J. Mol. Cell. Cardiol. 72:146–56.CrossRefGoogle Scholar
  37. 37.
    Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O’Brien KD. (1994) Characterization of the early lesion of ‘degenerative’ valvular aortic stenosis. Histological and immunohistochemical studies. Circulation. 90:844–53.CrossRefGoogle Scholar
  38. 38.
    Akira S. (2000) Toll-like receptors: lessons from knockout mice. Biochem. Soc. Trans. 28:551–56.CrossRefGoogle Scholar
  39. 39.
    Kawai T, Akira S. (2007) TLR signaling. Semin. Immunol. 19:24–32.CrossRefGoogle Scholar
  40. 40.
    Alexopoulou L, Holt A, Medzhitov R, Flavell R. (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 413:732–8.CrossRefGoogle Scholar
  41. 41.
    Zhan Q, et al. (2015) Activation of TLR3 induces osteogenic responses in human aortic valve interstitial cells through the NF-κB and ERK1/2 pathways. Int. J. Biol. Sci. 11:482.CrossRefGoogle Scholar
  42. 42.
    López J, et al. (2012) Viral and bacterial patterns induce TLR-mediated sustained inflammation and calcification in aortic valve interstitial cells. Int. J. Cardiol. 158:18–25.CrossRefGoogle Scholar
  43. 43.
    Zhan Q, et al. (2017) Double-stranded RNA up-regulates the expression of inflammatory mediators in human aortic valve cells through the TLR3-TRIF-non-canonical NF-κB pathway. Am. J. Physiol. Cell Physiol. 312:C407–17.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  • Qiong Zhan
    • 1
    • 2
  • Qingchun Zeng
    • 1
    • 2
  • Rui Song
    • 1
  • Yufeng Zhai
    • 1
  • Dingli Xu
    • 2
  • David A. Fullerton
    • 1
  • Charles A. Dinarello
    • 3
  • Xianzhong Meng
    • 1
    • 4
  1. 1.Department of SurgeryUniversity of Colorado DenverAuroraUSA
  2. 2.Department of Cardiology, Nanfang HospitalSouthern Medical UniversityGuangzhouChina
  3. 3.Department of MedicineUniversity of Colorado DenverAuroraUSA
  4. 4.AuroraUSA

Personalised recommendations